Hepatitis C virus core antigen for screening organ donors and recipients

Organ donors and recipients are routinely screened for hepatitis C virus (HCV) infection, typically via anti-HCV detection. We analyze the utility of an alternative HCV core antigen (HCV-Ag) quantification system, the ARCHITECT HCV Ag Assay, in this setting. We simultaneously tested 315 samples from potential organ donors and recipients using two chemiluminescent microparticle immunoassays: ARCHITECT Anti-HCV and HCV Ag (Abbott, Germany). HCV-Ag was detected in 81 of the serum samples (25.71%) and anti-HCV in 87 (27.62%).

Source: Diagnostic Microbiology and Infectious Disease - February 1, 2018 Category: Microbiology Authors: Rafael Benito, Jorge Arribas, Sonia Algarate, Roc ío Cebollada, M. José Gude Source Type: research